Evidence Generation for JCAs: How Can AI Boost Efficiency and Maintain Quality?
Missed our recent webinar on the role of AI in Joint Clinical Assessments (JCAs)? Catch the recording for a deep dive into how AI can enhance systematic literature reviews (SLRs) for health technology assessments (HTA) in the EU's new oncology and advanced therapy medicinal product regulations. Learn from industry experts about the benefits, challenges, and future of AI-supported SLRs in the compressed JCA timeline.
Starting in January 2025, as part of the EU HTA regulation, all new oncology and advanced therapy medicinal products will be subject to JCA. As stipulated in the JCA Implementing Act, systematic literature review (SLR) searches should be no older than three months, while the final scope of the JCA will only be issued 100 days prior to the submission deadline. This compressed timeline presents a challenge to ensure SLRs are conducted quickly while maintaining the rigor required for HTA.
The integration of AI in SLRs presents an opportunity to improve the efficiency and accuracy of evidence generation for JCAs. This webinar will explore how AI can support evidence generation for JCA and consider the potential benefits and challenges of this approach.
The webinar discussion will address the following key questions:
Moderator:
Speakers:
Meet OPEN Health experts at ISPOR Europe booth #913
Do you want to learn more about health technology assessments and the use of artificial intelligence in joint clinical assessments? Meet the OPEN Health speakers at ISPOREurope. We look forward to seeing you there.
Date: Tuesday, 19 November 2024
Time:18:00 – 19:00 CET (during the networking reception)
Location: The OPEN Health booth, 913
How could we support you?
Our mission is to solve complex challenges by bringing world-class scientific, strategic, and creative expertise to global biopharma.
For information about OPEN Health’s services and how we could support you, please visit our website or contact us.